NCT02719574 · OUTCOME
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation · Source last updated 2026-06-29
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure COUNT_OF_PARTICIPANTS
Unit Participants
Interval / dispersion Not reported
Time frame Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months) What was measured Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.
Analysis population: SAS analyzed. Since 150 mg BID has been established as MTD, the analysis was directed towards emphasizing findings that are most relevant for determining a safe and effective treatment strategy. Accordingly, data for the other dose levels (100 mg QD, 150 mg QD, and 300 mg QD) were combined as prespecified in SAP.
Groups in this outcome Phase 1: FT-2102 (Single Agent) Participants with AML or MDS received single agent FT-2102 orally BID in 28-day cycles at dose levels of 150 mg until maximum MTD or maximum MED achieved.
Phase 1: Total FT-2102 (Single Agent) Participants with AML or MDS received single agent FT-2102 orally QD and BID in 28-day cycles at the differ-ent dose levels (150 mg and ≤ 300 mg) until MTD or MED achieved.
Phase 1: FT-2102 + Azacitidine (Combination Therapy) Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\^2) orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.
Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) Participants with AML or MDS received combination therapy (FT-2102 150 mg and ≤ 300 mg and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count Phase 1: FT-2102 (Single Agent) 16 Phase 1: Total FT-2102 (Single Agent) 31 Phase 1: FT-2102 + Azacitidine (Combination Therapy) 39 Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 46
Reported measurements Hematology: Hemoglobin; Increase(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 30 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 38 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 45 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 9 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 20 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 30 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 36 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Hemoglobin; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 20 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 30 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 36 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 20 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 31 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 37 Not reported Not reported Not reported Not reported
Hematology: Platelets; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 25 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 36 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 43 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 28 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 36 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 43 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Hematology: Leukocytes: Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 23 Not reported Not reported Not reported Not reported
Hematology: Leukocytes; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 19 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 33 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 39 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 23 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 36 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 43 Not reported Not reported Not reported Not reported
Hematology: Neutrophils; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 28 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 38 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 45 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 19 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 26 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 32 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes: Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 6 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Hematology: Lymphocytes; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 23 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 23 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 26 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 31 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 11 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Creatinine; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 28 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 35 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 39 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 13 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 23 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 26 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Calcium; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 28 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 33 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 40 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Increase(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 8 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 17 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 24 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 26 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Magnesium; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 24 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 34 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 40 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Increase(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 16 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 21 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 23 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Potassium; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 27 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 34 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 41 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 3 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 15 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 17 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 11 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 24 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Sodium; Decrease (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 21 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 25 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 31 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 9 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 10 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Uric acid; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 3 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 4 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 12 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 10 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 12 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 16 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Albumin; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 13 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 26 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 33 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 40 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 14 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 29 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 32 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 39 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 5 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Glucose; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 2 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 18 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Lipase; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 4 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 5 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 19 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Chemistry: Amylase; Decrease(Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase(Grade <1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 6 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 7 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 20 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 21 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 1) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 1 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 2 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 2) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 3) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase(Grade 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 0 Not reported Not reported Not reported Not reported
Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3 or 4) Values in Participants · Interval/dispersion: Not reported Group Value Spread Lower Upper Comment Phase 1: FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102 (Single Agent) 0 Not reported Not reported Not reported Not reported Phase 1: FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) 1 Not reported Not reported Not reported Not reported
Complete source fields classes categories measurements
group Id OG000
value 15
group Id OG001
value 30
group Id OG002
value 38
group Id OG003
value 45
title Hematology: Hemoglobin; Increase(Grade <1) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Increase (Grade 1) categories measurements
group Id OG000
value 0
group Id OG001
value 1
group Id OG002
value 1
group Id OG003
value 1
title Hematology: Hemoglobin; Increase (Grade 2) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Increase (Grade 3) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Increase (Grade 4) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Increase (Grade 3 or 4) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Decrease (Grade <1) categories measurements
group Id OG000
value 3
group Id OG001
value 3
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Decrease (Grade 1) categories measurements
group Id OG000
value 1
group Id OG001
value 7
group Id OG002
value 9
group Id OG003
value 10
title Hematology: Hemoglobin; Decrease (Grade 2) categories measurements
group Id OG000
value 11
group Id OG001
value 20
group Id OG002
value 30
group Id OG003
value 36
title Hematology: Hemoglobin; Decrease (Grade 3) categories measurements
group Id OG000
value 0
group Id OG001
value 0
group Id OG002
value 0
group Id OG003
value 0
title Hematology: Hemoglobin; Decrease (Grade 4) categories measurements
group Id OG000
value 11
group Id OG001
value 20
group Id OG002
value 30
group Id OG003
value 36
title Hematology: Hemoglobin; Decrease(Grade 3 or 4) Show more (12 of 144) denoms counts
group Id OG000
value 16
group Id OG001
value 31
group Id OG002
value 39
group Id OG003
value 46
units Participants
description Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death. groups
description Participants with AML or MDS received single agent FT-2102 orally BID in 28-day cycles at dose levels of 150 mg until maximum MTD or maximum MED achieved.
id OG000
title Phase 1: FT-2102 (Single Agent)
description Participants with AML or MDS received single agent FT-2102 orally QD and BID in 28-day cycles at the differ-ent dose levels (150 mg and ≤ 300 mg) until MTD or MED achieved.
id OG001
title Phase 1: Total FT-2102 (Single Agent)
description Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\^2) orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.
id OG002
title Phase 1: FT-2102 + Azacitidine (Combination Therapy)
description Participants with AML or MDS received combination therapy (FT-2102 150 mg and ≤ 300 mg and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
id OG003
title Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy)
param Type COUNT_OF_PARTICIPANTS
population Description SAS analyzed. Since 150 mg BID has been established as MTD, the analysis was directed towards emphasizing findings that are most relevant for determining a safe and effective treatment strategy. Accordingly, data for the other dose levels (100 mg QD, 150 mg QD, and 300 mg QD) were combined as prespecified in SAP.
reporting Status POSTED
time Frame Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
title Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
type PRIMARY
unit Of Measure Participants Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle